Compare Citius Pharmaceuticals Inc (CTXR) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Global X Lithium & Battery Tech ETF — how do they compare? Citius Pharmaceuticals Inc trades at $0.5 (market cap $13.62M), while Global X Lithium & Battery Tech ETF trades at $69.72 (market cap $1.45B). The key difference: Global X Lithium & Battery Tech ETF is far larger — about 106.5× Citius Pharmaceuticals Inc's market cap, and Global X Lithium & Battery Tech ETF is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Citius Pharmaceuticals Inc for 17 Days and Global X Lithium & Battery Tech ETF for 56 Days on average.
| CTXR | LIT | |
|---|---|---|
Market Cap | $13.62M | $1.45B |
Volume | 132,438 | 89,392 |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $1.82 | $91.62 |
52-Week Low | $0.48 | $53.92 |
Typical Hold Time | 17 Days | 56 Days |
Enterprise Value | $3.79M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.4994, down 1.73% with a bearish technical signal despite oscillators showing oversold conditions. The company reported $7.1M revenue for the first nine months of 2026 from LYMPHIR commercial sales, but continues to post significant losses with a -651.27% net income margin. Recent news highlights strong commercial momentum for LYMPHIR with 44 institutions ordering the treatment since launch.
The stock presents a high-risk opportunity with analyst consensus strongly bullish (83% buy ratings, $5 price target) but fundamental challenges persist. Key risks include ongoing cash burn and execution of commercial strategy, while potential upside depends on successful LYMPHIR adoption and path to profitability.
LIT trades at $69.73, up 0.32% with mixed technical signals showing a bullish overall trend but bearish moving averages and oscillators. The ETF's price action remains volatile, trading near key support/resistance levels. Recent news highlights significant short interest reduction and ongoing exposure to the lithium and battery technology sector, which faces both supply chain challenges and long-term growth potential from electric vehicle adoption.
The outlook for LIT is cautiously optimistic, driven by global EV adoption trends and energy storage demand, though tempered by lithium price volatility and competitive pressures. Key risks include commodity price swings and geopolitical factors affecting battery supply chains, while institutional sentiment shows mixed signals with technical indicators suggesting near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
